• Machine Learning for Lipid Nanoparticle Prediction in mRNA V

  2026-05-27

  This study pioneers a machine learning-based approach to predict and optimize lipid nanoparticle (LNP) formulations for mRNA vaccine delivery, using LightGBM algorithms trained on experimental IgG titer data. The findings accelerate LNP design, highlight critical lipid substructures, and offer a computational complement to traditional screening, with practical implications for translational mRNA vaccine research.

• BRCA2 Limits PARP1 Retention to Stabilize RAD51 Filaments

  2026-05-27

  This study reveals a direct mechanistic link between BRCA2 and the cellular response to PARP inhibition. By demonstrating that BRCA2 prevents PARP inhibitor–mediated PARP1 retention at DNA breaks, the authors clarify why BRCA2-deficient tumors are highly sensitive to PARP inhibitors, with implications for homologous recombination deficient cancer treatment strategies.

• Nutlin-3a MDM2 Inhibitor: Optimizing Cancer Research Workflo

  2026-05-26

  Nutlin-3a is a benchmark MDM2 inhibitor that empowers researchers to precisely activate the p53 pathway, induce apoptosis, and dissect complex tumor suppressor mechanisms in cancer models. This guide translates cutting-edge bench research into actionable protocols, troubleshooting strategies, and innovative applications for reproducible and robust results.

• Novobiocin’s Antiviral Repurposing: Translational Insights f

  2026-05-26

  Explore how Novobiocin, a potent aminocoumarin antibiotic, is being repurposed as an antiviral compound with promising efficacy against SFTSV. This article delivers unique translational analysis and practical guidance for antiviral research workflows.

• Nutlin-3a MDM2 Inhibitor: Optimized Workflows for Cancer Res

  2026-05-25

  Nutlin-3a offers targeted p53 pathway activation, driving robust cell cycle arrest and apoptosis in preclinical cancer models. This article translates recent mechanistic findings and protocol advances into actionable workflows, maximizing reproducibility and experimental insight.

• Panobinostat (LBH589): Applied Workflows for Cancer Epigenet

  2026-05-25

  Panobinostat (LBH589) empowers researchers to dissect apoptosis induction and epigenetic regulation with unprecedented precision in cancer models. This guide delivers hands-on workflows, troubleshooting insights, and practical tips to maximize experimental clarity and reproducibility in translational oncology.

• 5hmC’s Context-Dependent Roles in Rice Drought Gene Regulati

  2026-05-24

  This study delivers the first single-base resolution map of 5-hydroxymethylcytosine (5hmC) in rice, revealing how its genomic localization shifts dynamically during drought stress and recovery. Key findings show that 5hmC plays bifunctional, context-dependent roles in gene regulation, providing new avenues for plant epigenetic research and crop resilience strategies.

• CUDC-907: Technical Application in Dual PI3K/HDAC Inhibition

  2026-05-23

  CUDC-907 addresses the need for precise, simultaneous inhibition of PI3K and HDAC pathways in controlled in vitro cancer research. It is not suitable for diagnostic, clinical, or therapeutic use, and should be applied only within validated laboratory protocols.

• Topotecan as a Topoisomerase I Inhibitor: Mechanistic Insigh

  2026-05-22

  This review details the pharmacological innovation of topotecan, a water-soluble, semisynthetic topoisomerase I inhibitor, highlighting its unique mechanism of action, pharmacokinetics, and clinical utility in solid tumors. The findings provide researchers with a nuanced understanding of topotecan's apoptosis induction in cancer cells and implications for combination chemotherapy regimens.

• AZ505: SMYD2 Inhibitor Workflows for Epigenetic and Cancer R

  2026-05-22

  AZ505 empowers researchers to dissect SMYD2-mediated methylation in cancer, fibrosis, and beyond with unprecedented specificity. This guide synthesizes the latest experimental protocols, troubleshooting insights, and strategic applications for maximizing the impact of this potent and selective SMYD2 inhibitor.

• Filipin III: Advancing Cholesterol Mapping in Pulmonary Fibr

  2026-05-21

  This thought-leadership piece explores how Filipin III, a polyene macrolide antibiotic, empowers translational researchers to decode cholesterol dynamics in pulmonary fibrosis models. By synthesizing mechanistic insights from recent studies on SOAT1-driven foam cell formation and expert workflow guidance, it establishes Filipin III as an indispensable tool for high-resolution membrane cholesterol visualization. The article highlights APExBIO's validated Filipin III, details protocol parameters, and positions the reagent within the broader landscape of cholesterol-driven disease research, while also addressing translational bridges, competitive advantages, and the future outlook for cholesterol-centric therapeutics and diagnostics.

• CA-074 Me: Potent, Selective Cathepsin B Inhibitor for Resea

  2026-05-21

  CA-074 Me is a highly selective, cell-permeable cathepsin B inhibitor with an IC50 of 36.3 nM. It is widely used to dissect lysosomal enzyme functions and cell death pathways, particularly necroptosis and apoptosis, in both in vitro and animal models. CA-074 Me’s robust performance and clear selectivity make it a gold standard for mechanistic studies in apoptosis assays and inflammation research.

• GRK Subtype Control of M1 Receptor Biased Signaling: Mechani

  2026-05-20

  This study elucidates how distinct GRK subtypes regulate biased downstream signaling of the M1 muscarinic acetylcholine receptor, revealing molecular mechanisms that shape the interaction with G proteins and β-arrestin. The findings offer new perspectives for selective modulation of M1 receptor pathways, with implications for cognitive function and Alzheimer's disease research.

• Direct-Detection mRNA: Advancing Delivery, Imaging, and Tran

  2026-05-20

  This thought-leadership article dissects the strategic and mechanistic advances in mRNA delivery and imaging, focusing on the integration of 5-methoxyuridine modifications and Cy3 labeling. Using APExBIO’s ARCA Cy3 EGFP mRNA (5-moUTP) as a model, we bridge recent breakthroughs in non-viral delivery—such as branched endosomal disruptor lipids—with practical guidance for translational researchers. The piece contextualizes these innovations within the rapidly evolving landscape of gene therapy and functional genomics, emphasizing experimental validation, workflow optimization, and the future outlook for mRNA therapeutics.

• Anti-ROR1 Antibody (Zilovertamab): Enabling Precision in Liv

  2026-05-19

  Anti-ROR1 Antibody (Zilovertamab) unlocks new precision in modeling Wnt5a-induced signaling inhibition, streamlining workflows in both liver injury and oncology research. Its validated specificity and robust performance make it the go-to choice for reproducible ELISA, FACS, and animal studies demanding high assay fidelity.

481 records 12/33 page Previous Next First page 上5页 1112131415 下5页 Last page